

APR. 29. 2005 9:33AM

TTC-PA 650-326-2422

RECEIVED  
CENTRAL FAX CENTER


NO. 6260 P. 1/13


APR 29 2005

PTO/SB/21 (04-04)

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/724,319
		Filing Date	November 27, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Nichols
Total Number of Pages in This Submission	13	Attorney Docket Number	15270J-004743US

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form (1 pg. submitted in duplicate) <input type="checkbox"/> Communication (2 pages) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (5 pgs) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Townsend and Townsend and Crew LLP Rosemarie L. Celli	
Signature		
Date	Reg. No. 42,397 April 29, 2005	

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Fax No. (703) 872-9306 on April 29, 2005.			
Typed or printed name	Christopher R. Fitting 		
Signature		Date	April 29, 2005

60479517 v1

RECEIVED  
MAY 2 2005  
CIVIL/JCWS

PTO/SB/17 (12-04)

Effective on 12/08/2004.  
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

# FEE TRANSMITTAL For FY 2005

Applicant claims small entity status. See 37 CFR 1.27

**TOTAL AMOUNT OF PAYMENT** (\$ 180.00)

Complete if Known	
Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk
Examiner Name	Nichols, C. J.
Art Unit	1647
Attorney Docket No.	15270J-004743US

## METHOD OF PAYMENT (check all that apply)

Check  Credit Card  Money Order  None  Other (please identify): \_\_\_\_\_  
 Deposit Account Deposit Account Number: 20-1430 Deposit Account Name: Townsend and Townsend and Crew LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below  Charge fee(s) indicated below, except for the filing fee  
 Charge any additional fee(s) or underpayments of fee(s)  Credit any overpayments  
 under 37 CFR 1.16 and 1.17

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038

## FEE CALCULATION

### 1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES	
	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)
Utility	300	150	500	250	200	100
Design	200	100	100	50	130	65
Plant	200	100	300	150	160	80
Reissue	300	150	500	250	600	300
Provisional	200	100	0	0	0	0

### 2. EXCESS CLAIM FEES

Fee Description	Small Entity
Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent	50 25
Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent	200 100
Multiple dependent claims	360 180

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims	Small Entity
-20 or HP =	x \$	= \$0		Fee (\$)	Fee (\$)

HP = highest number of total claims paid for, if greater than 20

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Small Entity
-3 or HP =	x \$	= \$0		Fee (\$)

HP = highest number of independent claims paid for, if greater than 3

### 3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 =	/ 50 =	(round up to a whole number) x		=

### 4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other: Information Disclosure Statement (after office action)

Fee Paid (\$)

180.00

## SUBMITTED BY

Signature	<i>Rosemarie L. Celli</i>	Registration No. (Attorney/Agent) 42,397	Telephone (650) 326-2400
Name (Print/Type)	Rosemarie L. Celli		Date April 29, 2005

60479603 v1

Effective on 12/08/2004.  
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

# FEE TRANSMITTAL For FY 2005

Applicant claims small entity status. See 37 CFR 1.27

**TOTAL AMOUNT OF PAYMENT** (\$ 180.00)

Complete if Known	
Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk
Examiner Name	Nichols, C. J.
Art Unit	1647
Attorney Docket No.	15270J-004743US

## METHOD OF PAYMENT (check all that apply)

Check  Credit Card  Money Order  None  Other (please identify): \_\_\_\_\_

Deposit Account Deposit Account Number: 20-1430 Deposit Account Name: Townsend and Townsend and Crew LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below  Charge fee(s) indicated below, except for the filing fee

Charge any additional fee(s) or underpayments of fee(s)  Credit any overpayments  
under 37 CFR 1.16 and 1.17

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038

## FEE CALCULATION

### 1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Small Entity		Small Entity		Small Entity		
	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	
Utility	300	150	500	250	200	100	_____
Design	200	100	100	50	130	65	_____
Plant	200	100	300	150	160	80	_____
Reissue	300	150	500	250	600	300	_____
Provisional	200	100	0	0	0	0	_____

### 2. EXCESS CLAIM FEES

#### Fee Description

Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent

Small Entity	
Fee (\$)	Fee (\$)
50	25
200	100
360	180

Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent

Multiple dependent claims

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims	Fee (\$)	Fee Paid (\$)
-20 or HP =	x	\$	\$0			
HP = highest number of total claims paid for, if greater than 20						

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
-3 or HP =	x	\$	\$0

HP = highest number of independent claims paid for, if greater than 3

### 3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 =	/ 50 =	(round up to a whole number) x		=

### 4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other: Information Disclosure Statement (after office action)

Fee Paid (\$)

180.00

## SUBMITTED BY

Signature	Rosemarie L. Celli	Registration No. (Attorney/Agent)	42,397	Telephone	(650) 326-2400
Name (Print/Type)	Rosemarie L. Celli			Date	April 29, 2005

60479803 v1

I hereby certify that this correspondence is being sent by facsimile transmission to: Commissioner for Patents at 703-872-9306

On April 29, 2005

TOWNSEND and TOWNSEND and CREW LLP  
 By: Ch. Felt

**PATENT**  
 Attorney Docket No.: 15270J-004743US  
 Client Reference No.: 209US-CIP5C3

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re application of:**

**Dale B. Schenk**

**Application No.: 09/724,319**

**Filed: November 27, 2000**

**For: PREVENTION AND TREATMENT  
 OF AMYLOIDOGENIC DISEASE**

**Examiner: Christopher J. Nichols**

**Art Unit: 1647**

**SUPPLEMENTAL INFORMATION  
 DISCLOSURE STATEMENT UNDER 37  
 CFR §1.97 and §1.98**

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of references 509, 517-542, 545-547, 549-561, 564-569, 571 and 579 can be found in Application No. 09/322,289, filed May 28, 1999 (Attorney Docket No. 15270J-004740US).

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98 issued as U.S. 6,787,523 on 09/07/04;

05/03/2005 EFLORES 00000099 201430 09724319

01 FC:1806 180.00 DA

Dale B. Schenk  
Application No.: 09/724,319  
Page 2

PATENT

09/497,553 filed 02/03/00;  
09/724,477 filed 11/28/00 issued as U.S. 6,787,143 on 09/07/04;  
09/723,927 filed 11/28/00 issued as U.S. 6,787,138 on 09/07/04;  
09/723,762 filed 11/28/00 issued as U.S. 6,787,144 on 09/07/04;  
09/724,102 filed 11/28/00 issued as U.S. 6,787,139 on 09/07/04;  
09/724,489 filed 11/28/00 issued as U.S. 6,787,140 on 09/07/04;  
10/816,022 filed 03/31/04 issued as U.S. 6,866,850 on 03/15/05;  
10/816,529 filed 03/31/04 issued as U.S. 6,818,218 on 11/16/04;  
10/815,391 filed 03/31/04 issued as U.S. 6,866,849 on 03/15/05;  
10/934,818 filed 09/02/04;  
10/934,609 filed 09/02/04 issue fee paid 01/24/05;  
10/933,559 filed 09/02/04 issue fee paid 01/24/05;  
10/934,819 filed 09/02/04;  
10/815,353 filed 03/31/04 issued as U.S. 6,808,712 on 10/26/04;  
10/816,380 filed 03/31/04 issue fee paid 01/24/05;  
10/815,404 filed 03/31/04 issue fee paid 11/12/04;  
09/322,289 filed 05/28/99;  
09/723,713 filed 11/27/00;  
09/723,760 filed 11/27/00;  
09/724,319 filed 11/27/00;  
09/723,384 filed 11/27/00 issued as U.S. 6,710,226 on 03/23/04;  
09/724,495 filed 11/27/00;  
10/788,666 filed 02/27/04;  
10/429,216 filed 05/30/03;  
10/828,548 filed 04/19/04;  
10/923,471 filed 08/20/04;  
10/923,474 filed 08/20/04;  
10/928,926 filed 08/27/04;  
10/923,605 filed 08/20/04;  
10/923,267 filed 08/20/04;

Dale B. Schenk  
Application No.: 09/724,319  
Page 3

PATENT

10/923,469 filed 08/20/04;  
09/580,015 filed 05/26/00;  
09/724,940 filed 11/28/00 issue fee paid 11/12/04;  
09/724,961 filed 11/28/00 issued as U.S. 6,743,427 on 06/01/04;  
09/580,018 filed 05/26/00 issued as U.S. 6,761,888 on 07/13/04;  
09/724,552 filed 11/28/00 issued as U.S. 6,750,324 on 06/15/04;  
09/723,544 filed 11/28/00;  
09/724,273 filed 11/28/00;  
09/724,551 filed 11/28/00 issued as U.S. 6,787,637 on 09/07/04;  
09/724,288 filed 11/28/00;  
10/777,792 filed 02/11/04;  
10/890,024 filed 04/12/04;  
10/889,999 filed 04/12/04;  
10/890,000 filed 07/12/04;  
10/890,070 filed 07/12/04;  
10/890,071 filed 07/12/04;  
09/580,019 filed 05/26/00;  
09/723,765 filed 11/28/00;  
09/724,291 filed 11/28/00;  
10/822,968 filed 04/12/04;  
09/724,929 filed 11/28/00;  
09/724,567 filed 11/28/00 issue fee paid 05/24/04;  
09/724,575 filed 11/28/00;  
09/724,953 filed 11/28/00 issued as U.S. 6,875,434 on 04/05/05;  
09/724,570 filed 11/28/00 issue fee paid 02/10/05;  
09/585,656 filed 06/01/00;  
09/723,766 filed 11/27/00;  
09/723,725 filed 11/27/00;  
09/579,690 filed 05/26/00;  
09/979,701 filed 03/13/01 (U.S. Nat'l Stage of PCT/US00/14810 filed 05/26/00);

Dale B. Schenk  
Application No.: 09/724,319  
Page 4

PATENT

09/979,952 filed 04/09/02 (U.S. Nat'l Stage of PCT/US00/15239 filed 06/01/00);  
issue fee paid 01/28/05; and,

09/980,568 filed 03/12/02 (U.S. Nat'l Stage of PCT/US00/15302 filed 06/01/00).

Applicant also cites the following copending applications directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01;  
10/789,273 filed 02/27/04;  
10/232,030 filed 08/30/02;  
10/010,942 filed 12/06/01;  
10/388,389 filed 03/12/03;  
10/703,713 filed 11/07/03;  
10/704,070 filed 11/07/03;  
10/388,214 filed 03/12/03;  
10/858,855 filed 06/01/04;  
10/771,174 filed 02/04/04.  
60/622,525 filed 10/26/04;  
60/636,684 filed 12/15/04;  
60/636,842 filed 12/15/04;  
60/637,253 filed 12/16/04;  
60/636,810 filed 12/15/04;  
60/637,138 filed 12/16/04;  
60/636,776 filed 12/15/04;  
60/636,687 filed 12/15/04.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;  
60/080,970 filed 04/07/98;  
60/067,219 filed 12/03/97;  
60/079,697 filed 03/27/98;

Dale B. Schenk  
Application No.: 09/724,319  
Page 5

PATENT

09/204,838 filed 12/03/98;  
09/724,921 filed 11/28/00;  
09/724,929 filed 11/28/00;  
60/137,010 filed 06/01/99;  
60/251,892 filed 12/06/00;  
60/137,047 filed 06/01/99;  
60/136,655 filed 05/28/99; and  
09/723,544 filed 11/28/00.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;  
60/474,654 filed 05/30/03;  
60/530,481 filed 12/17/03;  
60/444,150 filed 02/01/03; and,  
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;  
60/079,697 filed 03/27/98;  
09/204,838 filed 12/03/98;  
09/724,921 filed 11/28/00; and,  
09/724,929 filed 11/28/00.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she is invited to call the undersigned who will be happy to supply them.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant

Dale B. Schenk  
Application No.: 09/724,319  
Page 6


PATENT

information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

  
Rosemarie L. Celli  
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
RLC:crf

60479520 v1

→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

4

Complete if Known

Application Number	09/724,319
Filing Date	November 27, 2000
First Named Inventor	Schenk, D. B.
Art Unit	1647
Examiner Name	Nichols, C. J.

Attorney Docket Number 15270J-004743US

## U.S. PATENT DOCUMENTS

Examiner	Cite No.	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	578	6,875,434	04-05-2005	Schenk	
	577	6,866,849	03-15-2005	Schenk	
	575	6,866,850	03-15-2005	Schenk	
	576	6,818,218	11-16-2004	Schenk	
	563	6,787,637	09-07-2004	Schenk et al.	
	572	6,761,888	07-13-2004	Schenk	
	562	6,750,324	06-15-2004	Schenk et al.	
	573	6,743,427	06-01-2004	Schenk	
	544	2003/0147882 A1	08-07-2003	Solomon et al.	
	511	6,331,440	12-18-2001	Nordstedt, et al.	
	518	6,261,569	07-17-2001	Comis et al.	
	510	6,022,859	02-08-2000	Kiessling, et al.	
	512	5,891,991	04-06-1999	Wasco et al.	
	515	5,652,334	07-29-1997	Roberts	
	574	5,576,184	11-19-1996	Better et al.	
	513	5,514,548	05-07-1996	Krebber et al.	
	514	5,470,951	11-28-1995	Roberts	
	543	5,278,049	01-11-1994	Baker et al.	
	548	5,096,706	03-17-1992	Flint	
	570	4,912,206	03-27-1990	Goldgaber et al.	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60479618 v1

→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known	
				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, D. B.
				Art Unit	1647
				Examiner Name	Nichols, C. J.
Sheet	2	of	4	Attorney Docket Number	15270J-004743US

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### FOREIGN PATENT DOCUMENTS

Examiner Initiate <sup>a</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>c</sup>
		Country Code <sup>2</sup>	Number <sup>4</sup>	Kind Code <sup>3</sup> (if known)				
	533	AU	199870091		07-01-1999			
	523	EP	752 886	B1	01-28-1998			
	579	WO	04/031400	A2	04-15-2004			
	571	WO	04/13172	A2, A3	02-12-2004			
	557	WO	02/88307	A2	11-07-2002			
	556	WO	02/88306	A2	11-07-2002			
	529	WO	00/68263	A2	11-16-2000			
	519	WO	00/26238	A2	05-11-2000			
	555	WO	00/23082	A1	04-27-2000			
	522	WO	00/20027	A2	04-13-2000			
	528	WO	99/08587	A2	02-11-1999			
	520	WO	98/22120	A1	05-28-1998			
	530	WO	98/08868	A1	03-05-1998			
	521	WO	98/05350	A1	02-12-1998			
	525	WO	98/02462	A1	01-22-1998			
	527	WO	97/32017	A1	09-04-1997			
	528	WO	97/08320	A1	03-06-1997			
	532	WO	96/37621	A2	11-28-1996			
	518	WO	95/23166	A1	08-31-1995			
	531	WO	95/08999	A1	04-06-1995			
	524	WO	95/05393	A2	02-23-1995			
	517	WO	94/05311	A1	03-17-1994			

Examiner Signature		Date Considered
-----------------------	--	--------------------

<sup>a</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60479618 v1

→

PTO/SB/098 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
(use as many sheets as necessary)			
Sheet	3		
of	4		
		Attorney Docket Number	15270J-004743US

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	550	BARD et al., "Epitope and Isotype specificities of antibodies to $\beta$ -amyloid peptide for protection against Alzheimer's disease-like neuropathology," <u>PNAS</u> , 100(4):2023-2028 (2003).	
	561	BELLOTTI et al., "Application of Monoclonal Anti-Idiotypes in the Study of AL Amyloidosis: Therapeutic Implications," <u>Renal Failure</u> , 15(3):365-371 (1993).	
	558	BENJAMINI et al., from <u>IMMUNOLOGY A Short Course</u> , Second Edition, pages 136-138, 143, 73-74, 372-373, and 400-401, 1991, published by Wiley-Liss, Inc., New York, New York.	
	540	BENKIRANE, et al., "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," <u>J. Biol. Chem.</u> , 268(23):26279-26285 (1993).	
	542	CHISHTI et al., "Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695," <u>J. Biol. Chem.</u> , 276(24):21562-70 (2001).	
	566	CHOTHIA et al., "Domain Association in Immunoglobulin Molecules," <u>J. Mol. Biol.</u> , 186:651-663 (1985).	
	509	CIRRITO et al., "Amyloid $\beta$ and Alzheimer disease therapeutics: the devil may be in the details," <u>J. Clin. Invest.</u> , 112:321-323 (2000).	
	541	CRIBBS et al., "All-D-Erantiomers of Beta-Amyloid Exhibit Similar Biological Properties to All-L-Beta-Amyloids," <u>J. Biol. Chem.</u> , 272:7431-7436 (1997).	
	539	FINDEIS et al., "Modified peptide inhibitors of amyloid B-peptide polymerization," <u>Biochemistry</u> , 38:6781-6800 (1999).	
	538	LOOD, et al., "Topography of a binding site for small amnestic peptides deduced from structure-activity studies: Relation to amnestic effect of amyloid B protein," <u>PNAS</u> , 91:380-384 (1994).	
	565	FRAZER et al., "Immunoglobulins: Structure and Function," chapter 3, pages 37-74 from <u>Fundamental Immunology, fourth edition</u> , W.E. Paul, eds., Lippincott-Raven publishers, Philadelphia (1999).	
	559	HERLYN et al., "Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma," <u>Eur. J. Immunol.</u> , 9:657-659 (1979).	
	534	HOCK et al., "Antibodies against $\beta$ -Amyloid Slow Cognitive Decline in Alzheimer's Disease," <u>Neuron</u> , 38:542-554 (2003).	
	548	IRIZARRY et al., "A $\beta$ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse," <u>J. Neuroscience</u> , 17(18):7053-7059 (1997).	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60479618 v1

→  
 PTO/SB/08B (10-01)  
 Approved for use through 10/31/2002, OMB 0851-0031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	09/724,319
(use as many sheets as necessary)				Filing Date	November 27, 2000
				First Named Inventor	Schenk, D. B.
				Art Unit	1647
				Examiner Name	Nichols, C. J.
Sheet	4	of	4	Attorney Docket Number	15270J-004743US

560	JAHRLING et al., "Opsonization of Alphaviruses in Hamsters." <u>J. Medical Virology</u> , 12:1-16 (1983).	
547	KAYED et al., "Conformational Transitions of Islet Amyloid Polypeptide (IAPP) In Amyloid Formation <i>In Vitro</i> ." <u>J. Mol. Biol.</u> , 287:781-796 (1999).	
554	KETTLEBOROUGH et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation." <u>Protein Engineering</u> , 4(7):773-783 (1991).	
553	LEMERÉ et al., "Intranasal immunotherapy for the treatment of Alzheimer's disease: <i>Escherichia coli</i> LT and LT(R182G) as mucosal adjuvants." <u>Neurobiology of Aging</u> , 23(6):991-1000 (2002).	
551	LEVERONE et al., "A <sub>β</sub> 1-15 is less immunogenic than A <sub>β</sub> 1-40/42 for intranasal immunization of wild-type mice but may be effective for 'boosting'." <u>Vaccine</u> , 21:2197-2206 (2003).	
545	MASLIAH et al., "Comparison of Neurodegenerative Pathology In Transgenic Mice Overexpressing V717F $\beta$ -Amyloid Precursor Protein and Alzheimer's Disease." <u>J. Neuroscience</u> , 16(18):5795-5811 (1996).	
568	NOVOTNY et al., "Structural invariants of antigen binding: Comparison of immunoglobulin V <sub>L</sub> -V <sub>H</sub> and V <sub>L</sub> -V <sub>L</sub> domain dimers." <u>PNAS</u> , 82:4592-4596 (1985).	
564	PCT Search Report of 12/14/04 for application PCT/US04/02856	
536	SELA et al, "Different roles of D-amino acids in immune phenomena." <u>FASEB J.</u> , 11(6):449-456 (1999)..	
552	SIGURDSSON et al., "Immunization with a Nontoxic/Nonfibrillar Amyloid- $\beta$ Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology In Transgenic Mice." <u>Am. J. Pathology</u> , 159(2):439-447 (2001).	
549	SOLOMON, B., "Immunological approaches as therapy for Alzheimer's disease." <u>Expert Opin. Biol. Ther.</u> , 2(8):907-917 (2002).	
537	TJERNBERG, et al, "Controlling amyloid beta-peptide fibril formation with protease-stable ligands." <u>J. Biol. Chem.</u> , 272(19):12601-12605 (1997).	
535	VAN REGENMORTEL et al, "D-peptides as immunogens and diagnostic reagents." <u>Curr. Opin. Biotechnol.</u> , 9(4):377-382 (1998).	
569	VERSHIGORA A. E. OBSHCHAYA IMMUNOLOGIYA, pages 35, 229-231 and 152-153.	
567	WU et al., "An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity." <u>J. Exp. Med.</u> , 132:211-250 (1970).	

Examiner Signature		Date Considered
--------------------	--	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60479618 v1